SHINGRIX DIN 02570270
Status: Approved
Holder: GLAXOSMITHKLINE INC
Health Canada record
| Active ingredient(s) | VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN 50 MCG |
|---|
| Dosage form | Suspension |
|---|
| Route | Intramuscular |
|---|
| Schedule | SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | J07BK VARICELLA ZOSTER VACCINES |
|---|
| Original market date | |
|---|
| Current status date | 23-Jul-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02468425 | SHINGRIX | GLAXOSMITHKLINE INC | Suspension | VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN 50 MCG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37969 | 2026-07-23 | Supplement to a New Drug Submission (SNDS) | New formulation and presentation |
Request a quote for SHINGRIX
How to read a Canadian DIN record